CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleLevered free cash flow is $28.66M, above the global median of $16.24M
- PositionDebt-to-equity is 0×, lower than 95% of its Medical Devices peers (median 0.11×)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.15%Below 5Y avg (0.72%)
Annual Rate
CNY 0.03Paid annual
Payout Ratio
133.3%High
Last Ex-Dividend
May 6, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.38BCNY353.17M · vs all stocks (USD)
Trailing P/E
137.47xvs Medical Devices peers
Revenue (TTM)
342.66MCNY50.89M · vs all stocks (USD)
Profit Margin
5.19%vs Medical Devices peers
Beta
1.14xvs all stocks
52-Week Change
-26.35%vs all stocks
Market Capitalization
2.38BCNY353.17M · vs all stocks (USD)
Enterprise Value
2.17BCNY322.11M · vs all stocks (USD)
Trailing P/E
137.47xvs Medical Devices peers
PEG Ratio
4.12xvs Medical Devices peers
Price to Sales (TTM)
7.29xvs Medical Devices peers
Price to Book (MRQ)
3.10xvs Medical Devices peers
Enterprise to Revenue
6.33xvs Medical Devices peers
Enterprise to EBITDA
87.27xvs Medical Devices peers
Gross Margin
50.31%vs Medical Devices peers
Profit Margin
5.19%vs Medical Devices peers
Operating Margin
6.24%vs Medical Devices peers
Return on Assets (TTM)
0.57%vs Medical Devices peers
Return on Equity (TTM)
2.18%vs Medical Devices peers
Revenue (TTM)
342.66MCNY50.89M · vs all stocks (USD)
Revenue per Share (TTM)
2.89CNYUpdated Aug 20, 2026Quarterly Revenue Growth
4.70%vs Medical Devices peers
Gross Profit (TTM)
152.61MCNY22.66M · vs all stocks (USD)
EBITDA (TTM)
35.60MCNY5.29M · vs all stocks (USD)
Net Income (TTM)
17.80MCNY2.64M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
37.20%vs Medical Devices peers
Operating Cash Flow (TTM)
54.90MCNY8.15M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
192.98MCNY28.66M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0300CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
0.15%vs all stocks
5-Year Average Dividend Yield
0.72%vs all stocks
Payout Ratio
133.33%vs Medical Devices peers
Revenue
339.54MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
185.25MCNYFY2025 · Dec 31, 2025Gross Profit
154.29MCNYFY2025 · Dec 31, 2025Operating Income
13.70MCNY2.03M · vs all stocks (USD)
Pre-tax Income
16.74MCNYFY2025 · Dec 31, 2025Income Tax Expense
452.64KCNYFY2025 · Dec 31, 2025Net Income
16.29MCNYFY2025 · Dec 31, 2025EBIT
13.70MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
35.60MCNYFY2025 · Dec 31, 2025Research & Development
57.21MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
26.00MCNYFY2025 · Dec 31, 2025Other Operating Expenses
5.34MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
4.93MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
14.78MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.1400CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.1400CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
117.75MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
117.75MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
16.29MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
199.37KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
29.88MCNYFY2025 · Dec 31, 2025Free Cash Flow
-17.01MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
78.55MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
16.29MCNYFY2025 · Dec 31, 2025Other Non-cash Items
1.89MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-1.23MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
12.93MCNYFY2025 · Dec 31, 2025Capital Expenditures
-46.89MCNYFY2025 · Dec 31, 2025Purchase of Investments
-2.00MCNYFY2025 · Dec 31, 2025Sale of Investments
9.38MCNYFY2025 · Dec 31, 2025Other Investing Activity
41.90MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
2.40MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-3.67MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-24.24MCNYFY2025 · Dec 31, 2025Other Financing Charges
-12.34MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-40.25MCNYFY2025 · Dec 31, 2025Shares Outstanding
121.20MSharesUpdated Aug 20, 2026Float Shares
46.78MSharesUpdated Aug 20, 2026% Held by Insiders
62.35%vs all stocks
% Held by Institutions
0.38%vs all stocks
Total Cash (MRQ)
338.81MCNY50.32M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.80CNYUpdated Aug 20, 2026Total Debt (MRQ)
0.00CNYvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Medical Devices peers
Current Ratio (MRQ)
4.00xvs Medical Devices peers
Book Value per Share (MRQ)
6.65CNYUpdated Aug 20, 2026Total Assets
958.97MCNY142.43M · vs all stocks (USD)
Total Current Assets
549.85MCNYFY2025 · Dec 31, 2025Total Liabilities
154.68MCNYFY2025 · Dec 31, 2025Total Non-current Assets
409.12MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
2.55MCNYFY2025 · Dec 31, 2025Total Current Liabilities
152.14MCNYFY2025 · Dec 31, 2025Cash
148.57MCNYFY2025 · Dec 31, 2025Cash Equivalents
519.76KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
149.09MCNYFY2025 · Dec 31, 2025Other Short-term Investments
61.12MCNYFY2025 · Dec 31, 2025Accounts Receivable
55.07MCNYFY2025 · Dec 31, 2025Inventory
126.54MCNYFY2025 · Dec 31, 2025Accounts Payable
15.86MCNYFY2025 · Dec 31, 2025Other Current Liabilities
6.54MCNYFY2025 · Dec 31, 2025Common Stock (Book)
121.20MCNYFY2025 · Dec 31, 2025Retained Earnings
242.96MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
804.29MCNY119.45M · vs all stocks (USD)
52-Week Low
16.88CNYUpdated Aug 20, 202652-Week High
42.25CNYUpdated Aug 20, 202652-Week Change
-26.35%vs all stocks
Beta
1.14xvs all stocks
50-Day MA
19.66CNYUpdated Aug 20, 2026200-Day MA
24.37CNYUpdated Aug 20, 2026Avg 10-Day Volume
2.63MSharesUpdated Aug 20, 2026Avg 30-Day Volume
2.85MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
0.1500CNYUpdated Aug 20, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
How is this stock valued?
Close Below 40W SMA With Profitability
The price sits below its 40-week average, on three profitable years and cash above profit.
Reads
Where is this company structurally exposed?
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Medical Devices peers (median 0.11×)Notable
Debt-to-equity: 0.00Industry median: 0.11Industry P5: 0.00Peers compared: 102
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.50Profit Margin: 0.05
Financial Health
Altman Z-Score 10.48: safe zoneNotable
Altman Z-Score: 10.48
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Levered free cash flow is $28.66M, above the global median of $16.24MNotable
Levered free cash flow (USD): 28,661,403.858Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Suzhou Fushilai Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Shandong Sito Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang East-Asia Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Bionote Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Zhenyuan Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Hainan Huluwa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Standard Biotools Inc.
Tier 1ProductionApproval-Gated PipelineRule
Deva Holding A.S.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Aprilbio Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Cellectis S.A.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Guangdong Tecsun Science & Technology Co., Ltd.
3 interpretationsMinimal Tax and Interest DragPartial Recovery After Sharp DeclineClose Below 40W SMA With Profitability
Neosem Inc.
3 interpretationsMinimal Tax and Interest DragPartial Recovery After Sharp DeclineClose Below 40W SMA With Profitability
Kewell Technology Co., Ltd.
3 interpretationsMinimal Tax and Interest DragPartial Recovery After Sharp DeclineClose Below 40W SMA With Profitability